

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1-55. (canceled)

56. (currently amended) A method for inhibiting angiogenesis in a ~~mammal~~ tumor comprising administering to the ~~mammal~~ tumor an effective amount of an antibody or antigen binding fragment thereof that specifically binds and neutralizes a polypeptide comprising an amino acid sequence of SEQ ID NO:76.

57-68. (canceled)

69. (previously presented) The method of claim 56, wherein the polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO:75.

70. (previously presented) The method of claim 56, wherein said antibody is a polyclonal antibody, a monoclonal antibody, an antibody fragment, a human antibody, a humanized antibody, a chimeric antibody, a bispecific antibody or a heteroconjugate antibody.

71. (previously presented) The method of claim 70, wherein said antibody is an antagonist or a neutralizing antibody.

72. (previously presented) The method of claim 56, wherein the antibody has polyepitopic specificity.

73. (previously presented) The method of claim 56, wherein the antibody is a human antibody, a chimeric antibody, or a humanized antibody.

Please Do not enter

74. (previously presented) The method of claim 56, wherein the antibody is an antibody fragment.
75. (previously presented) The method of claim 74, wherein the antibody fragment comprises a Fab fragment, a Fab' fragment, a F(ab')<sub>2</sub> fragment, or a Fv fragment.
76. (previously presented) The method of claim 56, wherein the antibody is a heteroconjugate antibody.
77. (previously presented) The method of claim 73, wherein the antibody is a humanized antibody.
78. (new) The method of claim 56, wherein the tumor is a breast carcinoma, renal cell carcinoma, squamous cell carcinoma, colon carcinoma, and prostate carcinoma.
79. (new) The method of claim 78, wherein the tumor is a breast carcinoma.
80. (new) A method of inhibiting PMA-induced angiogenesis of endothelial cells, comprising administering to said endothelial cells an antibody or antigen binding fragment thereof that specifically binds and neutralizes a polypeptide comprising an amino acid sequence of SEQ ID NO:76.